RECODE THERAPEUTICS
LIVE

Serial Number

97354266

Owner

ReCode Therapeutics, Inc.

Attorney

Aaron D. Hendelman

Filing Date

Apr 8, 2022

Add to watchlist:

No watchlists yet
View on USPTO

RECODE THERAPEUTICS Trademark

Serial Number: 97354266

RECODE THERAPEUTICS is a trademark filed by ReCode Therapeutics, Inc. on April 8, 2022. The trademark is classified under Class 5 (Pharmaceuticals), Class 9 (Computers & Electronics), Class 41 (Education & Entertainment), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently pending registration.

Owner Contact Info

ReCode Therapeutics, Inc. (5 trademarks)

1140 O'Brien Drive
Menlo Park, CA 94025

Entity Type: 03

Trademark Details

Filing Date

April 8, 2022

Registration Date

Not Registered

Published for Opposition

March 28, 2023

Goods & Services

Medicines for the modification of genes and treatment of diseases, for use in the treatment of respiratory diseases, lung diseases, central nervous system diseases, immunodeficiency and autoimmune diseases, infectious diseases, liver diseases, metabolic disorders, muscular diseases, and cancer; cell and gene therapy biological preparations and pharmaceutical preparations with protein expression, all for the treatment of respiratory diseases, lung diseases, central nervous system diseases, immunodeficiency and autoimmune diseases, infectious diseases, liver diseases, metabolic disorders, muscular diseases, and cancer; drug carriers for medical use, namely, delivery agents in the form of non-viral lipid nanoparticles for delivering drugs to human organs that facilitate the delivery of a wide range of pharmaceuticals; pharmaceutical preparations for the treatment and prevention of respiratory diseases, lung diseases, central nervous system diseases, immunodeficiency and autoimmune diseases, infectious diseases, liver diseases, metabolic disorders, muscular diseases, and cancer

Downloadable electronic publications in the nature of articles, books, magazines, journals, and scientific texts in the fields of genetic medicine and drug delivery

Scientific and biotechnology research and analysis in the fields of cell and gene therapy and drug delivery; research and development of medicines and drug delivery platforms for the treatment of diseases; providing scientific research and medical research information in the fields of genetic medicine and drug delivery; medical and scientific research in the field of pharmaceuticals; pharmaceutical research and products development of pharmaceuticals for the treatment of respiratory diseases, lung diseases, central nervous system diseases, immunodeficiency and autoimmune diseases, infectious diseases, liver diseases, metabolic disorders, muscular diseases, and cancer

Providing online non-downloadable articles, books, magazines, journals, and scientific texts in the fields of genetic medicine and drug delivery

Providing medical information in the fields of genetic medicine and drug delivery

Filing History

NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
May 1, 2026 EXRA
SOU EXTENSION 5 GRANTED
Apr 30, 2026 EX5G
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Apr 27, 2026 AITU
SOU TEAS EXTENSION RECEIVED
Oct 31, 2025 EEXT
SOU EXTENSION 5 FILED
Oct 30, 2025 EXT5
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
May 9, 2025 EXRA
SOU EXTENSION 4 GRANTED
May 9, 2025 EX4G
SOU EXTENSION 4 FILED
May 8, 2025 EXT4
SOU TEAS EXTENSION RECEIVED
May 8, 2025 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Mar 3, 2025 EXRA
SOU EXTENSION 3 GRANTED
Nov 20, 2024 EX3G
SOU EXTENSION 3 FILED
Nov 20, 2024 EXT3
SOU TEAS EXTENSION RECEIVED
Nov 20, 2024 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
May 24, 2024 EXRA
SOU EXTENSION 2 GRANTED
May 23, 2024 EX2G
SOU EXTENSION 2 FILED
May 23, 2024 EXT2
SOU TEAS EXTENSION RECEIVED
May 23, 2024 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Nov 16, 2023 EXRA
SOU EXTENSION 1 GRANTED
Nov 14, 2023 EX1G
SOU EXTENSION 1 FILED
Nov 14, 2023 EXT1
SOU TEAS EXTENSION RECEIVED
Nov 14, 2023 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
May 23, 2023 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Mar 28, 2023 NPUB
PUBLISHED FOR OPPOSITION
Mar 28, 2023 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Mar 8, 2023 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Feb 18, 2023 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Feb 4, 2023 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Feb 4, 2023 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Feb 3, 2023 TROA
COMBINED EXAMINER'S AMENDMENT/PRIORITY ACTION ENTERED
Feb 1, 2023 CEPE
ASSIGNED TO LIE
Feb 1, 2023 ALIE
NOTIFICATION OF EXAMINER'S AMENDMENT/PRIORITY ACTION E-MAILED
Feb 1, 2023 GEAN
EXAMINER'S AMENDMENT/PRIORITY ACTION E-MAILED
Feb 1, 2023 GEAP
EXAMINERS AMENDMENT AND/OR PRIORITY ACTION - COMPLETED
Feb 1, 2023 CPEA
ASSIGNED TO EXAMINER
Jan 25, 2023 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Apr 13, 2022 NWOS
NEW APPLICATION ENTERED
Apr 12, 2022 NWAP